Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QURE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsuniQure plans UK regulatory filing for Huntington's gene therapy AMT-130 in Q3 2026
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
uniQure held pre-submission meeting with UK drug regulator (MHRA) for AMT-130, its experimental gene therapy for Huntington's disease, and plans to file Marketing Authorization Application in Q3 2026—a key step toward potential commercialization.
Item 8.01 view on EDGAR →
Summary
uniQure announced it has completed a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency for AMT-130, its investigational gene therapy targeting Huntington's disease. The company now plans to submit a Marketing Authorization Application in the third quarter of 2026, marking a critical regulatory milestone that could bring the therapy closer to market approval in the UK.
For retail investors, this represents meaningful progress in uniQure's pipeline development. Huntington's disease is a devastating genetic disorder with limited treatment options, and successful approval could open a significant commercial opportunity. The UK filing would be an important proof point for the therapy's viability and could pave the way for broader regulatory submissions.
Investors should watch for the actual Q3 filing confirmation and any subsequent regulatory feedback or approval timelines from the MHRA. Additionally, monitor whether uniQure announces parallel regulatory strategies in other markets, particularly the US and EU, which would signal broader commercial ambitions for AMT-130.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 16, 2026 · How we verify